切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2019, Vol. 13 ›› Issue (04) : 272 -276. doi: 10.3877/cma.j.issn.1674-0785.2019.04.006

所属专题: 文献

临床研究

Turbo Hawk斑块旋切系统治疗下肢动脉硬化闭塞症的疗效评估
管圣1,(), 杨建平1, 唐加热克1, 戈小虎1   
  1. 1. 830001 乌鲁木齐,新疆维吾尔自治区人民医院血管外科
  • 收稿日期:2018-08-21 出版日期:2019-02-15
  • 通信作者: 管圣

Efficacy of Turbo Hawk atherectomy system in treatment of lower extremity arteriosclerosis obliterans

Sheng Guan1,(), Jianping Yang1, Jiareke Tang1, Xiaohu Ge1   

  1. 1. Department of Vascular Surgery, People′s Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China
  • Received:2018-08-21 Published:2019-02-15
  • Corresponding author: Sheng Guan
  • About author:
    Corresponding author: Guan Sheng, Email:
引用本文:

管圣, 杨建平, 唐加热克, 戈小虎. Turbo Hawk斑块旋切系统治疗下肢动脉硬化闭塞症的疗效评估[J/OL]. 中华临床医师杂志(电子版), 2019, 13(04): 272-276.

Sheng Guan, Jianping Yang, Jiareke Tang, Xiaohu Ge. Efficacy of Turbo Hawk atherectomy system in treatment of lower extremity arteriosclerosis obliterans[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2019, 13(04): 272-276.

目的

探讨Turbo Hawk斑块旋切系统治疗股浅动脉硬化狭窄或闭塞患者的临床疗效及应用价值。

方法

本研究回顾分析新疆维吾尔自治区人民医院2016年1月至2017年12月经下肢动脉成像确诊股浅动脉硬化闭塞或狭窄,且使用Turbo Hawk斑块旋切系统治疗的60例患者的临床资料,评估术后患者临床症状改善程度、管腔通畅度及血流动力学改善情况。采用t检验比较术前术后患者股浅动脉病变处管腔狭窄程度和踝肱指数(ABI)的差异。

结果

60病例符合Rutherford分类法3~6级的患者,术后临床症状明显改善的占46.67%(28/60),术后临床症状中度改善占53.33%(32/60)。术后数字减影心血管造影术(DSA)示管腔狭窄程度较术前明显下降[(0.26±0.05)分vs (0.90±0.08)分],差异具有统计学意义(t=2.847,P=0.015),术后ABI较术前明显升高(0.85±0.11 vs 0.25±0.13),差异具有统计学意义(t=1.546,P=0.023)。

结论

Turbo Hawk斑块切除术可以清除股浅动脉硬化闭塞斑块,开通狭窄或闭塞的动脉管腔,改善患者临床症状,是一种有效地腔内减容方案。

Objective

To assess the clinical efficacy and application value of the Turbo Hawk atherectomy system in treating patients with superficial femoral artery stenosis or occlusion.

Methods

This study retrospectively analyzed the clinical data of 60 patients with superficial femoral arteriosclerosis occlusion or stenosis diagnosed by lower extremity artery imaging and treated with the TurboHawk plaque circumcision system at Xinjiang Uygur Autonomous Region Peoples Hospital from January 2016 to December 2017. The clinical symptoms, lumen stenosis degree, and ankle brachial index (ABI) of patients with superficial femoral artery lesions before and after operation were observed to evaluate the improvement of clinical symptoms, lumen patency, and hemodynamics.

Results

Of the 60 patients who had grades 3-6 disease according to the Rutherford classification criteria, 46.67% (28/60) showed significant improvement in clinical symptoms after surgery, and 53.33% (32/60) showed moderate improvement in clinical symptoms Postoperative digital subtraction angiography (DSA) showed a significant decrease in lumen stenosis compared with preoperative value (0.26±0.05 vs 0.9±0.08, t=2.847, P=0.015). Postoperative ABI was significantly higher than preoperative value (0.85±0.11 vs 0.25±0.13, t=1.546, P=0.023).

Conclusion

Turbo Hawk plaque resection can remove the plaque of superficial femoral arteriosclerosis occlusion, open the narrowed or occluded arterial lumen, and improve the clinical symptoms, representing an effective intraluminal volume reduction method.

表1 60例下肢动脉硬化闭塞症患者Rutherford分级及临床表现
表2 术后Rutherfor临床疗效评估标准
表3 60例下肢动脉硬化闭塞症患者旋切术前、术后管腔狭窄程度和ABI比较(±s
图1 股浅动脉狭窄患者术前和术后CTA及造影术结果
1
中华医学会外科学分会血管外科学组. 下肢动脉硬化性闭塞症治疗指南 [J]. 中国实用外科杂志, 2008, 28(11): 923-924.
2
Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC Ⅱ) [J]. Eur J Vasc Endovasc Surg, 2007, 33 Suppl 1: S1-75.
3
Laird JR, Yeo KK. The treatment of femoropopliteal instent restenosis: back to the future [J]. J Am Coll Cardiol, 2012, 59(1): 24-25.
4
Yeo KK, Mail U, Laird JR. Outcomes following treatment of femoropopliteal in-stent restenosis: a single-center experience [J]. Catheter Cardiovasc Interv, 2011, 78(4): 604-608.
5
Roberts D, Niazi K, Miller W, et al. DEFINITIVE Ca++ Investigators.Effective endovascular treatment of calcified femoropopliteal disease with directional atherectomy and distal embolic protection: final results of the DEFINITIVE Ca++ trial [J]. Catheter Cardiovasc Interv, 2014, 84(2): 236-244.
6
Rutherford RB, Baker DJ, Ernst C, et al. Recommended standards for reports dealing with Lower extremity ischemia: Revised version [J]. J Vasc Surg, 2001, 33(4): 805-808.
7
Lusis AJ. Atherosclerosis [J]. Nature, 2000, 407(6801): 233-241.
8
Criqui MH, Aboyans V. Epidemiology of peripheral artery disease [J]. Circ Res, 2015, 116(9): 1509-1526.
9
Katsanos K, Tepe G, Tsetis D. Standards of practice for superficial femoral and popliteal artery angioplasty and stenting [J]. Cardiovasc Interv Radiol, 2014, 37(3): 592-603.
10
Shammas NW. An overview of optimal endovascular strategy in treating the femoropopliteal artery: mechanical, biological, and procedural factors [J]. Int J Angiol, 2013, 22(1): 1-8.
11
Babaev A, Gokhale R, Zavlunova S, et al. Treatment of Angio-Seal-Related Femoral Artery Occlusion Using Directional Atherectomy—Primary Results and Midterm Follow-Up [J]. Vasc Endovascular Surg, 2016, 50(8): 541-546.
12
Bracale UM, Vitale G, Bajardi G, et al. Use of the directional atherectomy for the treatment of femoro-popliteal lesions in patients with critical lower limb ischemia [J]. Transl Med UniSa, 2016, 15(6): 42-47.
13
Mittleider D, Russell E. Peripheral atherectomy: applications and techniques [J]. Tech Vasc Interv Radiol, 2016, 19(2): 123-135.
14
Stavroulakis K, Bisdas T, Torsello G, et al. Combined directional atherectomy and drug-eluting balloon angioplasty for isolated popliteal artery lesions in patients with peripheral artery disease [J]. J Endovasc Ther, 2015, 22(6): 847-852.
15
Stavroulakis K, Schwindt A, Torsello G, et al. Directional atherectomy with antirestenotic therapy vs drug-coated balloon angioplasty alone for isolated popliteal artery lesions [J]. J Endovasc Ther, 2017, 24(2): 181-188.
16
McKinsey, JF, Zeller T, Rocha-Singh KJ, et al. Lower Extremity revascularization using directional atherectomy: 12-month prospective results of the DEFINITIVE LE study [J]. JACC Cardiovasc Interv, 2014, 7(8): 923-933.
[1] 张启龙, 柳亿, 卢会丽, 罗慧, 李成林, 王菁, 王辉. 奥妥珠单抗治疗磷脂酶A2受体相关膜性肾病的疗效与安全性:单中心回顾性分析[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(05): 379-384.
[2] 王杰, 袁泉, 王玥琦, 乔佳君, 谭春丽, 夏仲元, 刘守尧. 溃疡油在糖尿病足溃疡治疗中的应用效果及安全性观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 480-484.
[3] 聂生军, 王钰, 王毅, 鲜小庆, 马生成. 复方倍他米松局部注射联合光动力疗法治疗小型瘢痕疙瘩的临床疗效观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(05): 404-410.
[4] 李义亮, 苏拉依曼·牙库甫, 麦麦提艾力·麦麦提明, 克力木·阿不都热依木. 机器人与腹腔镜食管裂孔疝修补术联合Nissen 胃底折叠术短期疗效分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 512-517.
[5] 周艳, 李盈, 周小兵, 程发辉, 何恒正. 不同类型补片联合Nissen 胃底折叠术修补食管裂孔疝的疗效及复发潜在危险因素[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 528-533.
[6] 王小琴, 汪丽, 崔建英. 无张力疝修补术治疗慢性肾功能衰竭合并腹股沟疝患者的疗效[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 538-542.
[7] 王亚岚, 倪婧, 余世庆, 陶银花, 张荣. 尼达尼布抗纤维化治疗特发性肺纤维化的耐受性和疗效预测因素分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 750-755.
[8] 詹济玮, 蔡柳春, 温琼娜, 郭石生, 温春妹, 温鹤明. 布地格福联合噻托溴铵治疗AECOPD 的临床分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 823-826.
[9] 魏孔源, 仵正, 王铮, 黎韡. 机器人胰腺中段切除后远端胰腺消化道不同重建方式初探[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(05): 295-300.
[10] 梁艳娉, 列诗韵, 王艺穗, 吴晓瑛, 林颖. 基于内镜操作细节记录系统构建胃底静脉曲张内镜下组织胶注射术的标准化管理方案[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 705-709.
[11] 陈杰, 武明胜, 李一金, 李虎, 向源楚, 荣新奇, 彭健. 低位直肠癌冷冻治疗临床初步分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 494-498.
[12] 史彬, 司远. 益气和络方联合缬沙坦治疗气阴两虚兼血瘀证IgA 肾病的疗效观察[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 306-312.
[13] 韩俊岭, 王刚, 马厉英, 连颖, 徐慧. 维生素D 联合匹维溴铵治疗腹泻型肠易激综合征患者疗效及对肠道屏障功能指标的影响研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 560-564.
[14] 阳跃, 庹晓晔, 崔子豪, 欧阳四民, 林海阳, 胡景宇, 胡银, 李涛, 赵景峰, 郝岱峰, 冯光. 改良“阅读者”皮瓣修复骶尾部压疮的疗效[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 751-755.
[15] 克地尔牙·马合木提, 胡波, 杨琼, 闫素, 胡岚卿, 高沛沛, 姚恩生. 依达拉奉右莰醇对急性脑梗死后认知功能障碍的疗效观察[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(05): 459-466.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?